risankizumab
Intravenous: Restricted to gastrointestinal physicians in the outpatient setting.
Subcutaneous: Inpatients may use home supply.
Reviewed: Jan 2023 (Skyrizi SQ), March 2024 (Skyrizi IV)
Spotlight Risankizumab (Skyrizi)
Risankizumab, Intravenous (Skyrizi) Crohn's Disease Induction
Intravenous: Restricted to gastrointestinal physicians in the outpatient setting.
Subcutaneous: Inpatients may use home supply.
Reviewed: Jan 2023 (Skyrizi SQ), March 2024 (Skyrizi IV)
Spotlight Risankizumab (Skyrizi)
Risankizumab, Intravenous (Skyrizi) Crohn's Disease Induction